"Silent" MIs Outweigh "Scary" Bleeds, FDA Concludes In Effient Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's approval of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel) reflects the review team’s willingness to look past the increased risk of bleeding – a dramatic and viscerally alarming adverse event, though understandable due to the medical setting – to see the less immediately apparent benefit of a reduction in a type of cardiac event that includes so-called "silent MIs" that have no visible clinical presentation.
You may also be interested in...
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.
Bleeding Rates In TRA-2P Further Dim Outlook For Merck’s Vorapaxar
Outcomes study of about 25,000 patients shows novel antiplatelet drug reduces events but also increases major bleeding, including intracranial hemorrhage.
FDA Updates Plavix Label, Leaves Effient With Clear Advantage
FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.